{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:48:48Z","timestamp":1791236928669,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:00:00Z","timestamp":1674259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.clinthera.2023.01.005","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T20:30:07Z","timestamp":1678825807000},"page":"437-455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Blood Pressure\u2013lowering Effect of Fimasartan Versus Comparators: A Cross-inference With a Systematic Review and Meta-analysis Through a Quality-management System"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4022-5998","authenticated-orcid":false,"given":"Hojin","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang-Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duk-Woo","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Mo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2023.01.005_bib0001","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.bmcl.2011.12.116","article-title":"Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists","volume":"22","author":"Kim","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0002","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2165\/11593840-000000000-00000","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects","volume":"11","author":"Chi","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0003","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.clinthera.2013.06.021","article-title":"Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension","volume":"35","author":"Lee","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0004","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s40265-016-0592-1","article-title":"Fimasartan: a new angiotensin receptor blocker","volume":"76","author":"Lee","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0005","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.clinthera.2012.01.024","volume":"34","author":"Lee","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0006","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.clinthera.2014.07.004","article-title":"Efficacy and safety of 30-mg fimasartan for the treatment of patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, Phase III clinical study","volume":"36","author":"Youn","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0007","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.clinthera.2016.04.005","article-title":"A randomized, double-blind, candesartan-controlled, parallel group comparison clinical trial to evaluate the antihypertensive efficacy and safety of fimasartan in patients with mild to moderate essential hypertension","volume":"38","author":"Lee","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0008","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3904\/kjim.2016.094","article-title":"24-Hour blood pressure response to lower dose (30 mg) fimasartan in Korean patients with mild to moderate essential hypertension","volume":"32","author":"Lee","year":"2017","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0009","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2147\/DDDT.S231293","volume":"14","author":"Chung","year":"2020","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0010","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/9516279","article-title":"Systematic review with network meta-analysis: comparative efficacy and safety of combination therapy with angiotensin II receptor blockers and amlodipine in Asian hypertensive patients","volume":"2019","author":"Lee","year":"2019","journal-title":"Int J Hypertens"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0011","doi-asserted-by":"crossref","first-page":"PA53","DOI":"10.1016\/j.jval.2011.02.299","article-title":"Extension of meta-analysis in comparing of fimasartan with losartan in blood pressure lowering effect","volume":"14","author":"Na","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0012","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0013","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0014","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is 583 blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0016","series-title":"Cochrane Handbook for Systematic Reviews of Interventions, Chapter 16","article-title":"Special topics in statistics","author":"Higgins","year":"2021"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0017","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analysis","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0018","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/bmj.323.7304.101","article-title":"Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis","volume":"323","author":"Sterne","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0019","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis","volume":"54","author":"Sterne","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0020","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/insr.12232","article-title":"Modern likelihood-frequentist inference","volume":"85","author":"Pierce","year":"2017","journal-title":"Int Stat Rev"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0021","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00019053-200725080-00003","article-title":"The contrast and convergence of Bayesian and frequentist statistical approaches in pharmacoeconomic analysis","volume":"25","author":"Skrepnek","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0022","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/j.jacc.2004.01.035","article-title":"Prior convictions: Bayesian approaches to the analysis and interpretation of clinical megatrials","volume":"43","author":"Diamond","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0023","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1016\/j.clinthera.2015.02.019","article-title":"A randomized, multicenter, double-blind, placebo-controlled, 3\u00a0\u00d7\u00a03 factorial design, Phase III study to evaluate the efficacy and safety of the combination of fimasartan\/amlodipine in patients with essential hypertension","volume":"37","author":"Lee","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0024","unstructured":"R-Pharm. Efficacy and safety evaluating study to compare Knarb (fimasartan) and Cozaar (losartan) in adult patients with grade I-II arterial hypertension. 2020 [cited 2021 September 23]. ClinicalTrials.gov. U.S. National Library of Medicine [Internet]. Available from: http:\/\/clinicaltrials.gov\/show\/NCT02248961."},{"key":"10.1016\/j.clinthera.2023.01.005_bib0025","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/clc.23133","article-title":"Comparison of fimasartan and amlodipine therapy on carotid atherosclerotic plaque inflammation","volume":"42","author":"Oh","year":"2019","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0026","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40264-014-0239-7","article-title":"The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases","volume":"38","author":"Abraham","year":"2015","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0027","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.biopha.2017.07.091","article-title":"Renin-angiotensin-aldosterone (RAAS): the ubiquitous system for homeostasis and pathologies","volume":"94","author":"Patel","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0028","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.clinthera.2021.06.001","article-title":"Efficacy and tolerability of evogliptin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis with Bayesian inference through a quality-management system","volume":"43","author":"Oh","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0029","doi-asserted-by":"crossref","first-page":"20938","DOI":"10.1038\/s41598-021-00418-z","article-title":"Antidiabetic effect of gemigliptin: a systematic review and meta-analysis of randomized controlled trials with Bayesian inference through a quality management system","volume":"11","author":"Oh","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0030","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1248\/bpb.b16-00987","article-title":"Pharmacological profiles of a highly potent and long-acting angiotensin II receptor antagonist, fimasartan, in rats and dogs after oral administration","volume":"40","author":"Paik","year":"2017","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0031","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/s41598-018-19998-4","article-title":"Central and cerebral haemodynamic changes after antihypertensive therapy in ischaemic stroke patients: a double-blind randomized trial","volume":"8","author":"Choi","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0032","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7836527","article-title":"Comparison of the effect of fimasartan versus valsartan on blood pressure variability in acute ischemic stroke: a double-blind randomized trial","volume":"2019","author":"Shin","year":"2019","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0033","article-title":"Fimasartan reduces clinic and home pulse pressure in elderly hypertensive patients: a K-MetS study","volume":"14","author":"Cho","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0034","doi-asserted-by":"crossref","first-page":"118","DOI":"10.12793\/tcp.2018.26.3.118","article-title":"Safety and efficacy of fimasartan with essential hypertension patients in real world clinical practice: data from a post marketing surveillance in Korea","volume":"26","author":"Han","year":"2018","journal-title":"Tansl Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0035","doi-asserted-by":"crossref","first-page":"309","DOI":"10.18705\/1607-419X-2016-22-3-309-315","article-title":"Pharmacokinetics of fimasartan, a novel angiotensin II receptor type 1 antagonist in Russian population","volume":"22","author":"Kobalava","year":"2016","journal-title":"Arterial'naya Gipertenziya\" (\"Arterial Hypertension\")"},{"key":"10.1016\/j.clinthera.2023.01.005_bib0036","first-page":"316","article-title":"Safety and efficacy of fimasartan in Mexican patients with grade 1-2 essential hypertension","volume":"87","author":"Cardona-Mu\u00f1oz","year":"2017","journal-title":"Arch Cardiol Mex"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823000255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823000255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T19:04:58Z","timestamp":1719342298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291823000255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0149291823000255"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.01.005","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blood Pressure\u2013lowering Effect of Fimasartan Versus Comparators: A Cross-inference With a Systematic Review and Meta-analysis Through a Quality-management System","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}